PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). Procept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On February 25, 2026, the Company announced earnings results for its fourth fiscal quarter and year ending December 31, 2025, disclosing that, contrary to prior assurances that U.S. handpiece sales were largely commensurate with procedures, handpiece sales had in fact materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Due to this inventory glut, the Company revealed that quarterly handpiece unit sales in the U.S. had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%, resulting in the Company widely missing its annual revenue guidance by tens of millions of dollars. On this news, the price of Procept shares fell from $27.84 per share on February 25, 2026 to $22.69 per share on February 27, 2026, a decline of more than 18% over a two-day trading period, on above-average trading volume.